References

Leishmaniasis: current situation and new perspectives

10.1016/j.cimid.2004.03.004 · 2004 · External reference

10.1016/s0140-6736(18)31204-2

10.1016/s0140-6736(18)31204-2 · 2018 · External reference

Global distribution maps of the leishmaniases

10.7554/elife.02851 · 2014 · External reference

10.1371/journal.pntd.0008001

10.1371/journal.pntd.0008001 · 2020 · External reference

Leishmaniasis: pathogenesis, host immunity, and the evolving landscape of immunotherapy and immunochemotherapy

10.3389/fmicb.2026.1861933 · 2026 · External reference

Cutaneous leishmaniasis

10.1016/s1473-3099( · 2007 · External reference

Drug Discovery for Cutaneous Leishmaniasis: A Review of Developments in the Past 15 Years

10.3390/microorganisms11122845 · 2023 · External reference

10.1371/journal.pntd.0005739

10.1371/journal.pntd.0005739 · 2017 · External reference

10.1016/j.jaad.2014.08.051

10.1016/j.jaad.2014.08.051 · 2015 · External reference

The immunobiology of Leishmania braziliensis infection

10.3389/fimmu.2012.00145 · 2012 · External reference

Current Visceral Leishmaniasis Research: A Research Review to Inspire Future Study

10.1155/2018/9872095 · 2018 · External reference

Variations in visceral leishmaniasis burden, mortality and the pathway to care within Bihar, India

10.1186/s13071-017-2530-9 · 2017 · External reference

Visceral Leishmaniasis and the Skin: Dermal Parasite Transmission to Sand Flies

10.3390/pathogens11060610 · 2022 · External reference

Leishmaniasis: the act of transmission

10.1016/j.pt.2021.07.003 · 2021 · External reference

Leishmania development in sand flies: parasite-vector interactions overview

10.1186/1756-3305 · 2012 · External reference

Leishmania species: models of intracellular parasitism

10.1242/jcs.112.18.2993 · 1999 · External reference

Promastigote-to-Amastigote Conversion in Leishmania spp.—A Molecular View

10.3390/pathogens11091052 · 2022 · External reference

Review of the current treatments for leishmaniases

2012 · External reference

Use of Antimony in the Treatment of Leishmaniasis: Current Status and Future Directions

10.4061/2011/571242 · 2011 · External reference

Pentavalent Antimonials: New Perspectives for Old Drugs

10.3390/molecules14072317 · 2009 · External reference

Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis

10.1590/0037-8682-0213-2016 · 2016 · External reference

Selection and phenotype characterization of potassium antimony tartrate-resistant populations of four New World Leishmania species

10.1007/s00436-010-1852-8 · 2010 · External reference

Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis

10.1093/jac/dks275 · 2012 · External reference

Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations

10.3390/pharmaceutics15010099 · 2022 · External reference

Antiparasitic Drugs in the United States-Two Roads to High Prices

10.3389/fsoc · 2020 · External reference

Leishmania Vaccines: the Current Situation with Its Promising Aspect for the Future

10.3347/kjp.2022.60.6.379 · 2022 · External reference

The role of modern drug discovery in the fight against neglected and tropical diseases

10.1039/c4md00011k · 2014 · External reference

Phenotypic drug discovery: recent successes, lessons learned and new directions

10.1038/s41573-022-00472-w · 2022 · External reference

10.1371/journal.pntd.0006052

10.1371/journal.pntd.0006052 · 2017 · External reference

Global distribution of treatment resistance gene markers for leishmaniasis

10.1002/jcla.24599 · 2022 · External reference

Hit and lead criteria in drug discovery for infectious diseases of the developing world

10.1038/nrd4683 · 2015 · External reference

A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

10.1177/108705719900400206 · 1999 · External reference

10.1371/journal.pntd.0006157

10.1371/journal.pntd.0006157 · 2017 · External reference

Development of a target-free high-throughput screening platform for the discovery of antileishmanial compounds

10.1016/j.ijantimicag.2019.07.013 · 2019 · External reference

Synthesis and biological evaluation of 4,7,9-trisubstituted benzoxazepines as antileishmanial agents

10.1016/j.bmcl.2024.130003 · 2024 · External reference

Effective Tetradentate Compound Complexes against Leishmania spp. that Act on Critical Enzymatic Pathways of These Parasites

10.3390/molecules24010134 · 2018 · External reference

Library of Seleno-Compounds as Novel Agents against Leishmania Species

10.1128/aac.02546-16 · 2017 · External reference

A Multi-Species Phenotypic Screening Assay for Leishmaniasis Drug Discovery Shows That Active Compounds Display a High Degree of Species-Specificity

10.3390/molecules25112551 · 2020 · External reference

In vitro screening test using Leishmania promastigotes stably expressing mCherry protein

10.1128/aac.02224-13 · 2014 · External reference

An in vitro system for developmental and genetic studies of Leishmania donovani phosphoglycans

10.1016/s0166-6851(03)00142-7 · 2003 · External reference

Characterization of micro RNA expression profiles in L eishmania -infected human phagocytes

10.1111/pim.12156 · 2015 · External reference

Unresolved reference

1964 · External reference

A Lipophosphoglycan-Independent Method for Isolation of Infective Leishmania Metacyclic Promastigotes by Density Gradient Centrifugation

10.1006/expr.2001.4656 · 2001 · External reference

SAR refinement of antileishmanial N2,N4-disubstituted quinazoline-2,4-diamines

10.1016/j.bmc.2015.02.020 · 2015 · External reference

The Leishmania Parasitophorous Vacuole Membrane at the Parasite-Host Interface

2019 · External reference

Mannose receptor (MR) and Toll-like receptor 2 (TLR2) influence phagosome maturation during Leishmania infection

10.1111/pim.12521 · 2018 · External reference